Greenwich LifeSciences

Greenwich LifeSciences will eye a valued future at $460 a share, with GP2 leading the way.

White_valkyrie

Not Invested

Community Contributor

Published

09 Mar 25

Updated

10 Mar 25

Views

731

n/a

White_valkyrie's Fair Value

n/a

-20.1%

5.2%

-20.1%

5.2%

You can edit this narrative until May 14 2:40 AM. Then, changes will post as Updates.

Author's Valuation

US$46097.7% undervalued

White_valkyrie's Fair Value

Narrative

Updates1

Shared on 10 Mar 25

White_valkyrie made no meaningful changes to valuation assumptions.

White_valkyrie'sFair Value

US$460

97.7% undervalued

Future estimation in

Est. Revenue

Current revenue growth rate

85.73%

Biotech revenue growth rate

9.82%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.03%

Calculation

US$414.63m

Earnings '29

26.00x

PE Ratio '29

US$10.78b

Market Cap '29

US$10.78b

Market Cap '29

14.55m

No. shares '29

US$740.83

Share Price '29

US$740.83 Share Price '29

Discounted to 2024 @ 10.00% p.a.

US$460.00

Fair Value '24